Showing results (141-150 of 192) with videos related to

Sort By:
Pageof 20
Nature Communications|June 14, 2022
Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradationYingying Shen, Chaojie Lu, Zhengbo Song, et al.
Journal of Extracellular Vesicles|March 27, 2024
Proton pump inhibitors enhance macropinocytosis-mediated extracellular vesicle endocytosis by inducing membrane v-ATPase assemblyXinliang Lu, Zhengbo Song, Jiayue Hao, et al.
NPJ Precision Oncology|April 1, 2022
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangementsYongchang Zhang, Zhe Huang, Liang Zeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm TrialZhengbo Song, Dongqing Lv, Shi-Qing Chen, et al.
Signal Transduction and Targeted Therapy|November 3, 2024
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumorsWei Li, Yongsheng Wang, Anwen Xiong, et al.
Nature Communications|July 4, 2019
Fas signaling-mediated TH9 cell differentiation favors bowel inflammation and antitumor functionsYingying Shen, Zhengbo Song, Xinliang Lu, et al.
BMC Cancer|July 31, 2023
Development and validation of prognostic nomogram for T1-3N0M0 non-small cell lung cancer after curative resectionWeijian Mei, Wang Yao, Zhengbo Song, et al.
Translational Lung Cancer Research|March 15, 2021
A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancerZhihua Zhu, Zhengbo Song, Wenjie Jiao, et al.
Theranostics|January 22, 2024
Blockade of CD93 in pleural mesothelial cells fuels anti-lung tumor immune responsesChengyan Zhang, Xi Nan, Bei Zhang, et al.
Signal Transduction and Targeted Therapy|July 14, 2024
SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 studyZiming Li, Zhengbo Song, Wei Hong, et al.
Pageof 20